The main theme of the 2023 HTA conference is the new role that HTA and Negotiations are called upon to take on, in the context of new EU Regulation on Health Technology Assessment which will allow vital and innovative health technologies – such as innovative medicines, certain medical devices, medical equipment and prevention and treatment methods – to be more widely available. To this end, we have to work together to set goals for an innovative future.
For the health technology assessment (HTA) community to transition and for individual HTA bodies to find their place in a more proactive, global ecosystem that considers whole system value, key questions must be urgently addressed with stakeholders across the lifecycle.
In addition, the role of HTA and Negotiations Committee in health policy as primarily a tool for setting priorities, allocating resources, budgeting, and re-evaluating/ re-negotiating, in an ever-changing environment, with digital technologies and big data promising access to data that will lead to greater transparency and better-informed decisions.
The conference will offer an opportunity to discuss in depth the strategies, procedures, skills and capabilities needed to address challenges and overcome potential barriers to access to many new and innovative therapies.
Last but not least, after 5 years of operation of the HTA Committee and the Medicines’ Price Negotiation Committee, it is the right time to take a look back and reference to their difficulties, challenges and achievements as well as to assess the impact of these reforms on Greece’s pharmaceutical policy.